The TREAT‐NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia
暂无分享,去创建一个
Domenica Taruscio | Emma Heslop | Jes Rahbek | Christophe Béroud | Hanns Lochmüller | Petr Brabec | Clemens Bloetzer | Rosário Santos | Sabina Gainotti | Svetlana Artemieva | Karen Rafferty | Lawrence Korngut | Craig Campbell | Richard Roxburgh | Volker Straub | Kevin M Flanigan | Mireille Claustres | Sylvie Tuffery-Giraud | Manuel Posada | Francesc Palau | K. Bushby | K. Flanigan | D. Taruscio | C. Béroud | Hanns Lochmüller | M. Claustres | M. Posada | H. Dawkins | D. Salgado | Jorge Oliveira | F. Leturcq | A. Ambrosini | M. Rodrigues | R. Roxburgh | C. Campbell | N. Butoianu | H. Topaloglu | V. Karcagi | S. Lynn | S. Gainotti | E. Heslop | M. Walter | V. Straub | S. Monges | K. Rafferty | B. Lindvall | P. Brabec | N. Barišić | S. Tuffery-Giraud | Serap Inal | Rosário Santos | V. Rašić | Anna Ambrosini | Olivia Schreiber | Anna Lusakowska | Vedrana Milic Rasic | Veronika Karcagi | Agnes Herczegfalvi | Soledad Monges | Teodora Chamova | Velina Guergueltcheva | Niculina Butoianu | Miriam Rodrigues | Hugh Dawkins | Jaana Lahdetie | David Salgado | Jan Kirschner | Kate Bushby | Jan Verschuuren | A. Moresco | J. Kirschner | C. Bloetzer | Catherine L Bladen | Yi Dai | Nina Barišić | Maggie C Walter | Venkatarman Viswanathan | Farhad Bayat | En Kimura | Janneke C van den Bergen | Elena Neagu | Haluk Topaloğlu | Angela Stringer | Andriy V Shatillo | Ann S Martin | L. Korngut | H. Peay | A. Karaduman | A. Roy | F. Palau | France Leturcq | R. Ben Yaou | Stephen Lynn | V. Guergueltcheva | Holly Peay | Björn Lindvall | Angélica Moresco | Anna Roy | Tea Kos | Rabah Ben Yaou | Isis de la Caridad Guerrero Sarmiento | Francesca Ceradini | Jorge Oliveira | Ayşe Karaduman | Serap Inal | Piraye Oflazer | Brigitta von Rekowski | A. Shatillo | P. Oflazer | J. Verschuuren | E. Kimura | E. Neagu | T. Chamova | Ann S. Martin | A. Lusakowska | C. Bladen | Á. Herczegfalvi | J. C. van den Bergen | A. Stringer | Farhad Bayat | O. Schreiber | J. Lahdetie | J. Rahbek | S. Artemieva | T. Kos | V. Viswanathan | Y. Dai | Brigitta von Rekowski | Isis de la Caridad Guerrero Sarmiento | F. Ceradini | J. Oliveira | H. Topaloğlu
[1] Volker Straub,et al. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France , 2012, Neuromuscular Disorders.
[2] K. Bushby,et al. Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations. , 2009, Advances in experimental medicine and biology.
[3] P. Baxter. Treatment of the heart in Duchenne muscular dystrophy , 2006, Developmental medicine and child neurology.
[4] L. Kunkel,et al. The structural and functional diversity of dystrophin , 1993, Nature Genetics.
[5] Y. Hayashi,et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy) , 2013, Orphanet Journal of Rare Diseases.
[6] G. van Ommen,et al. Advances in therapeutic RNA-targeting. , 2013, New biotechnology.
[7] Christophe Béroud,et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.
[8] W. Gowers,et al. A Manual of Diseases of the Nervous System , 1887, Edinburgh Medical Journal.
[9] G. van Ommen,et al. Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.
[10] R. Griggs,et al. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? , 2013, Neurology.
[11] H. Peay. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? , 2013, Neurology.
[12] R. Griggs,et al. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice , 2013, Muscle & nerve.
[13] Kevin M Flanigan,et al. The Muscular Dystrophies , 1999, Seminars in Neurology.
[14] L. Dodds,et al. Duchenne Muscular Dystrophy: A 30-Year Population-Based Incidence Study , 2010, Clinical pediatrics.
[15] A. Emery. Duchenne muscular dystrophy or Meryon's disease , 2001, The Lancet.
[16] Matthew Bellgard,et al. The New Zealand Neuromuscular Disease Registry , 2012, Journal of Clinical Neuroscience.
[17] Christophe Béroud,et al. Genotype–phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD–DMD database: a model of nationwide knowledgebase , 2009, Human mutation.
[18] K. Bushby,et al. Collaborating to bring new therapies to the patient--the TREAT-NMD model. , 2009, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[19] T. Pavlík,et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach , 2009, Neuromuscular Disorders.
[20] A. Emery,et al. The muscular dystrophies , 2002, The Lancet.
[21] E. Hoffman,et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. , 2012, Physical medicine and rehabilitation clinics of North America.
[22] Christophe Béroud,et al. 157th ENMC International Workshop: Patient registries for rare, inherited muscular disorders 25–27 January 2008 Naarden, The Netherlands , 2008, Neuromuscular Disorders.
[23] S. Pandya,et al. Mutation Analysis in a Population-Based Cohort of Boys With Duchenne or Becker Muscular Dystrophy , 2009, Journal of child neurology.
[24] J. Pépin,et al. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[25] Volker Straub,et al. TREAT-NMD workshop: Pattern recognition in genetic muscle diseases using muscle MRI 25–26 February 2011, Rome, Italy , 2012, Neuromuscular Disorders.
[26] J. T. Dunnen,et al. Copy number variation in the genome; the human DMD gene as an example , 2006, Cytogenetic and Genome Research.
[27] R. Finkel,et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.
[28] M. Koenig,et al. Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.
[29] A. Emery. Duchenne muscular dystrophy—Meryon's disease , 1993, Neuromuscular Disorders.